CDEK
← All drugs Report issue

nafithromycin

Small moleculeexperimental

Clinical trial activity

6 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Mar 14, 2013 (NCT03926962)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2[C@H](/C(N)=N/O[C@@H](C)c3nnc(-c4ccccn4)s3)C(=O)O[C@@]21C
Mol. weight
859.06 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • nafithromycin
  • nafithromycin
  • wck 4873

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03981887Phase 1Jun 17, 2019Clinartis, Keystone Bioanalytical, Inc., Spaulding Clinical Research Inc., Wockhardt
NCT02903836Phase 2Sep 1, 2016ACM Global Laboratories, Wockhardt
NCT02770404Phase 1Apr 1, 2016Wockhardt
NCT02453529Phase 1Apr 1, 2015Clinartis, Wockhardt
NCT03979859Phase 1Aug 20, 2013Wockhardt
NCT03926962Phase 1Mar 14, 2013Wockhardt
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
WockhardtFor profit6622013
ClinartisFor profit2012015
ACM Global LaboratoriesFor profit1012016
Keystone Bioanalytical, Inc.For profit1012019
Spaulding Clinical Research Inc.For profit1012019
5 organizations
Page 1 / 1